Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Constipation - Pipeline Review, H1 2018, provides an overview of the Constipation (Gastrointestinal) pipeline landscape.
Constipation refers to the infrequent or difficult passing of stool. Constipation occurs when bowel movements become difficult or less frequent. Symptoms of constipation include swollen abdomen or abdominal pain, pain and vomiting. The predisposing factors include eating disorders, irritable bowel syndrome, and hypothyroidism, overuse of laxatives (stool softeners) which, over time, weaken the bowel muscles, stress, inadequate water intake and inadequate fiber in the diet. Treatment includes use of laxatives and proper lifestyle.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Constipation - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Constipation (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Constipation (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Constipation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 4, 9, 2, 3 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Constipation (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Constipation (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Constipation (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Constipation (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Constipation (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Constipation (Gastrointestinal)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Constipation (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Constipation (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Constipation - Pipeline Review, H1 2018
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Constipation - Overview
Constipation - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Constipation - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Constipation - Companies Involved in Therapeutics Development
Albireo Pharma Inc
Allergan Plc
Ardelyx Inc
Astellas Pharma Inc
Braintree Laboratories Inc
Dong-A ST Co Ltd
EA Pharma Co Ltd
Ironwood Pharmaceuticals Inc
Johnson & Johnson
NGM Biopharmaceuticals Inc
RaQualia Pharma Inc
Sanwa Kagaku Kenkyusho Co Ltd
SK Biopharmaceuticals Co Ltd
Sucampo Pharmaceuticals Inc
Sumitomo Dainippon Pharma Co Ltd
Synergy Pharmaceuticals Inc
Synthetic Biologics Inc
Vanda Pharmaceuticals Inc
Yuhan Corp
Zensun (Shanghai) Sci & Tech Co Ltd
Constipation - Drug Profiles
5-BIOP - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AJG-555 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-7663 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic for Irritable Bowel Syndrome with Constipation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLI-400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLI-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DA-6886 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DSP-6952 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
elobixibat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ENT-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
J-027 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
linaclotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
linaclotide DR2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lovastatin MR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lubiprostone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naronapride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NGM-282 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
plecanatide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
prucalopride succinate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
relenopride hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00000010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SK-1202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tenapanor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YH-12852 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZS-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Constipation - Dormant Projects
Constipation - Discontinued Products
Constipation - Product Development Milestones
Featured News & Press Releases
Jan 03, 2018: Ardelyx Successfully Completes T3MPO-3 Safety Extension Study of Tenapanor for IBS-C
Dec 19, 2017: Synergy Pharmaceuticals Appoints Troy Hamilton Chief Executive Officer
Nov 27, 2017: Application for Marketing and Manufacturing Approval of Chronic Constipation Treatment AJG555 Was Filed in Japan
Nov 09, 2017: Synergy Pharmaceuticals Provides Update on TRULANCE
Oct 16, 2017: Allergan to Present New Data on Gastrointestinal Drug Candidate Linaclotide at the World Congress of Gastroenterology at ACG 2017
Oct 16, 2017: Ardelyx Announces Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 Signaling
Oct 12, 2017: Synergy Pharmaceuticals to Highlight New Data for TRULANCE (Plecanatide) at the World Congress of Gastroenterology at American College of Gastroenterology
Oct 11, 2017: Ardelyxs Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018
Sep 28, 2017: Sucampo Pharmaceuticals Announces FDA Acceptance of sNDA for AMITIZA in Children with Pediatric Functional Constipation, with Priority Review Designation
Sep 11, 2017: Astellas Submits Supplemental New Drug Application for Approval of Additional Indication of "Linaclotide" for Patients with Chronic Constipation in Japan
Jun 27, 2017: Synthetic Biologics Announces Allowance of Key U.S. Patent Covering SYN-010 Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation
Jun 07, 2017: Synergy Pharmaceuticals Announces Acceptance of Supplemental New Drug Application (sNDA) for TRULANCE (Plecanatide) for the Treatment of Adults with Irritable Bowel Syndrome with Constipation
May 12, 2017: Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C
May 09, 2017: Ironwood Pharmaceuticals Presents Data Further Elucidating Linaclotide's Effect on Pain at Digestive Disease Week 2017
May 07, 2017: Synergy Pharmaceuticals to Present TRULANCE (Plecanatide) Phase 3 Data at Digestive Disease Week for the Treatment of Adults with Chronic Idiopathic Constipation with Moderate to Very Severe Bloating
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Constipation, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Constipation - Pipeline by Albireo Pharma Inc, H1 2018
Constipation - Pipeline by Allergan Plc, H1 2018
Constipation - Pipeline by Ardelyx Inc, H1 2018
Constipation - Pipeline by Astellas Pharma Inc, H1 2018
Constipation - Pipeline by Braintree Laboratories Inc, H1 2018
Constipation - Pipeline by Dong-A ST Co Ltd, H1 2018
Constipation - Pipeline by EA Pharma Co Ltd, H1 2018
Constipation - Pipeline by Ironwood Pharmaceuticals Inc, H1 2018
Constipation - Pipeline by Johnson & Johnson, H1 2018
Constipation - Pipeline by NGM Biopharmaceuticals Inc, H1 2018
Constipation - Pipeline by RaQualia Pharma Inc, H1 2018
Constipation - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H1 2018
Constipation - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2018
Constipation - Pipeline by Sucampo Pharmaceuticals Inc, H1 2018
Constipation - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2018
Constipation - Pipeline by Synergy Pharmaceuticals Inc, H1 2018
Constipation - Pipeline by Synthetic Biologics Inc, H1 2018
Constipation - Pipeline by Vanda Pharmaceuticals Inc, H1 2018
Constipation - Pipeline by Yuhan Corp, H1 2018
Constipation - Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H1 2018
Constipation - Dormant Projects, H1 2018
Constipation - Discontinued Products, H1 2018
List of Figures
Number of Products under Development for Constipation, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
Global Thyroid Gland Disorders Treatment Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 80
Thyroid Gland Disorder Treatment is a kind of treatment method, which aims to The thyroid disorder patients, such as hypothyroidism patients and hyperthyroidism patients. When The thyroid gland does not produce sufficient hypothyroidism or too much hyperthyroidism, The body metabolism and functioning will be disrupted.
The global Thyroid Gland Disorders Treatment market was valued at US$ 2950 million in 2023 and is anticipated to reach US$ 3871.9 million by 2030, witnessing a CAGR o......
Global Brachytherapy Afterloaders, Brachytherapy Seeds Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 98
According to our LPI (LP Information) latest study, the global Brachytherapy Afterloaders, Brachytherapy Seeds market size was valued at US$ 150.8 million in 2023. With growing demand in downstream market, the Brachytherapy Afterloaders, Brachytherapy Seeds is forecast to a readjusted size of US$ 168.1 million by 2030 with a CAGR of 1.6% during review period.
The research report highlights the growth potential of the global Brachytherapy Afterloaders, Brachytherapy Seeds market. Brachyth......
Global Peptide Therapeutics Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 109
According to our LPI (LP Information) latest study, the global Peptide Therapeutics market size was valued at US$ 33800 million in 2023. With growing demand in downstream market, the Peptide Therapeutics is forecast to a readjusted size of US$ 63130 million by 2030 with a CAGR of 9.3% during review period.
The research report highlights the growth potential of the global Peptide Therapeutics market. Peptide Therapeutics are expected to show stable growth in the future market. However, pr......
Global Microbiome Therapeutics Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 155
According to our LPI (LP Information) latest study, the global Microbiome Therapeutics market size was valued at US$ 89 million in 2023. With growing demand in downstream market, the Microbiome Therapeutics is forecast to a readjusted size of US$ 916.3 million by 2030 with a CAGR of 39.5% during review period.
The research report highlights the growth potential of the global Microbiome Therapeutics market. Microbiome Therapeutics are expected to show stable growth in the future market. H......
Global Anti-inflammatory Therapeutics Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 109
According to our LPI (LP Information) latest study, the global Anti-inflammatory Therapeutics market size was valued at US$ 108140 million in 2023. With growing demand in downstream market, the Anti-inflammatory Therapeutics is forecast to a readjusted size of US$ 166150 million by 2030 with a CAGR of 6.3% during review period.
The research report highlights the growth potential of the global Anti-inflammatory Therapeutics market. Anti-inflammatory Therapeutics are expected to show stabl......
Global Enzyme Replacement Therapy Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 113
According to our LPI (LP Information) latest study, the global Enzyme Replacement Therapy market size was valued at US$ 11570 million in 2023. With growing demand in downstream market, the Enzyme Replacement Therapy is forecast to a readjusted size of US$ 29900 million by 2030 with a CAGR of 14.5% during review period.
The research report highlights the growth potential of the global Enzyme Replacement Therapy market. Enzyme Replacement Therapy are expected to show stable growth in the f......
Global Infantile Spasms Therapeutics Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 84
According to our LPI (LP Information) latest study, the global Infantile Spasms Therapeutics market size was valued at US$ 138.9 million in 2023. With growing demand in downstream market, the Infantile Spasms Therapeutics is forecast to a readjusted size of US$ 179.6 million by 2030 with a CAGR of 3.7% during review period.
The research report highlights the growth potential of the global Infantile Spasms Therapeutics market. Infantile Spasms Therapeutics are expected to show stable grow......
Global Hormone Replacement Therapy Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 128
According to our LPI (LP Information) latest study, the global Hormone Replacement Therapy market size was valued at US$ 16090 million in 2023. With growing demand in downstream market, the Hormone Replacement Therapy is forecast to a readjusted size of US$ 17930 million by 2030 with a CAGR of 1.6% during review period.
The research report highlights the growth potential of the global Hormone Replacement Therapy market. Hormone Replacement Therapy are expected to show stable growth in th......
Global Plasma Therapy Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 107
According to our LPI (LP Information) latest study, the global Plasma Therapy market size was valued at US$ 265.3 million in 2023. With growing demand in downstream market, the Plasma Therapy is forecast to a readjusted size of US$ 529.4 million by 2030 with a CAGR of 10.4% during review period.
The research report highlights the growth potential of the global Plasma Therapy market. Plasma Therapy are expected to show stable growth in the future market. However, product differentiation, ......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
